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ABSTRACT
Background A small number of patients with variant
Creutzfeldt-Jakob disease (vCJD) have been treated with
intraventicular pentosan polysulfate (iPPS) and extended
survival has been reported in some cases. To date, there
have been no reports on the ﬁndings of postmortem
examination of the brain in treated patients and the
reasons for the extended survival are uncertain. We
report on the neuropathological ﬁndings in a case of
vCJD treated with PPS.
Methods Data on survival in vCJD is available from
information held at the National CJD Research and
Surveillance Unit and includes the duration of illness in
176 cases of vCJD, ﬁve of which were treated with iPPS.
One of these individuals, who received iPPS for 8 years
and lived for 105 months, underwent postmortem
examination, including neuropathological examination of
the brain.
Results The mean survival in vCJD is 17 months, with
40 months the maximum survival in patients not treated
with PPS. In the 5 patients treated with PPS survival was
16 months, 45 months, 84 months, 105 months and
114 months. The patient who survived 105 months
underwent postmortem examination which conﬁrmed the
diagnosis of vCJD and showed severe, but typical,
changes, including neuronal loss, astrocytic gliosis and
extensive prion protein (PrP) deposition in the brain. The
patient was also given PPS for a short period by
peripheral infusion and there was limited PrP
immunostaining in lymphoreticular tissues such as spleen
and appendix.
Conclusions Treatment with iPPS did not reduce the
overall neuropathological changes in the brain. The
reduced peripheral immunostaining for PrP may reﬂect
atrophy of these tissues in relation to chronic illness
rather than a treatment effect. The reason for the long
survival in patients treated with iPPS is unclear, but a
treatment effect on the disease process cannot be
excluded.
Variant Creutzfeldt-Jakob disease (vCJD) is a zoo-
notic prion disease, linked to infection with the
agent of bovine spongiform encephalopathy. There
is no proven treatment for the underlying disease
process. The suggestion, based on cell culture
results, that quinacrine might be an effective treat-
ment has not been conﬁrmed by assessments of the
efﬁcacy of this drug.1 2 In 2004 animal studies
provided evidence that intraventricular pentosan
polysulfate (iPPS) might be an effective treatment
in prion diseases3 and following a hearing in the
High Court, which supported the provision of this
treatment in vCJD, a small number of patients were
treated with iPPS. One patient did not appear to
respond to this treatment,4 but three others have
been reported to have extended survival in com-
parison with that expected in vCJD5 6 and a ﬁfth
patient has been conﬁrmed by reports in the media
to have had long survival.
The reason for the extended survival is unknown
and possibilities include a treatment effect, selec-
tion for treatment of patients likely to have long
survival, high quality care, including early treat-
ment of infection and chance.7 An observational
study of the efﬁcacy of iPPS concluded that there
was some suggestion of a treatment effect7 and the
Medical Research Council review on which this
paper was based suggested that PPS was a potential
therapy for prion disease. The possibility of a treat-
ment effect has been raised by the report of a
reduction in the amount of disease-associated prion
protein (PrP) in the brain of a case of sporadic CJD
treated with iPPS.8 This report describes the post-
mortem ﬁndings in a case of vCJD treated with
iPPS.
METHODS
The National CJD Research and Surveillance Unit
obtains data on all cases of vCJD in the UK. The
methodology of the Unit has been described in
detail previously. Information on clinical features,
including date of onset and death, together with
details of drug therapy is obtained on all cases.
Detailed information on the surgical procedures
and PPS infusion in this case were provided by con-
tributing authors (NVT, PKN). The results of the
whole blood assay for vCJD were provided by
author SM.
Postmortem examination was carried out by
author DS at the request of the coroner and tissues
were examined at the National CJD Research and
Surveillance Unit using a standard protocol
described previously. The methodologies for other
investigations in this case, including western blot
analysis, protease-resistant PrP (PrPres) sodium
phosphotungstic acid precipitation and genetic ana-
lysis have also been described previously.9
Ethical approval for the acquisition and use of
autopsy material for research at the Edinburgh
brain bank is covered by 11/ES/0022.
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RESULTS
There have been 177 deaths from vCJD in the UK (as of August
2013) and the mean survival is 17 months from disease onset to
death. Five of these cases received treatment with iPPS and the
duration of illness in these cases is shown in ﬁgure 1, together
with that of non-treated cases. The treated case that survived
105 months is described below.
Case report
An 18-year-old girl presented in September 2003 with a
9 month history of personality change, anxiety, tearfulness and
withdrawal. She performed unexpectedly badly in school exami-
nations and in July developed forgetfulness and unsteadiness
walking. The cognitive problems progressed and were associated
with ﬂeeting delusions and auditory hallucinations. She devel-
oped unpleasant sensory symptoms in the feet, slurring of
speech and ﬁdgety movements of the hands and arms. On
examination there was cognitive impairment, together with dys-
arthria, limb and gait ataxia and choreiform movements in the
limbs.
There was a past history of vertigo in 2002, with normal
MRI brain scan, but no history of treatment with human growth
hormone or prior neurosurgery and no family history of a
similar disorder. MRI brain scan in 2003 showed the ‘pulvinar’
sign and no other cause for the presentation was apparent on
extensive investigation. The clinical diagnosis was probable
vCJD. Testing for abnormal PrP in blood in August 2011, using
the novel assay described by Edgeworth et al,10 was negative.
After careful and full consideration of ethical and legal issues
in a patient who lacked capacity, the clinicians accepted the
wishes of the patient’s family to begin treatment with iPPS
which commenced in October 2003. Biventricular catheters
were inserted using a stereotactic procedure and a program-
mable pump was implanted subcutaneously. Treatment with
iPPS was given at a dosage of 11 μg/kg/day and following
replacement of the catheters in 2011 the treatment was contin-
ued at 11 μg/kg/day up until the patient died. In 2007, add-
itional systemic treatment with PPS was given by programmable
pump via the external jugular vein in a dosage increasing from
1mg/kg/day to 4 μg/kg/day. The treatment was stopped after
12 weeks because of persisting infection and haematoma at the
pump site, and the pump was removed.
Despite the treatment there was neurological deterioration
and by December 2003 the patient was unable to walk and
needed assistance to dress, bathe, wash and feed. There was
difﬁculty with swallowing and a percutaneous endoscopic gas-
trostomy tube was ﬁtted in June 2005. Over subsequent years
the patient’s condition was relatively static with only subtle
further clinical deterioration. She was wheelchair bound and
fully dependent for activities of daily living. There was no
verbal or clear sentient response, but at times the parents
reported transient responsiveness to outside stimuli such as the
pet dog or family videos, contrary to clinical observations. The
patient received excellent care from her family, with additional
nursing support and regular treatment by a physiotherapist.
The patient died suddenly in November 2011 and post-
mortem was carried out at the request of the coroner. The
patient’s family gave consent for detailed pathological investiga-
tion of the brain and peripheral tissues.
Postmortem results
The general postmortem revealed pulmonary oedema and mild
bronchopneumonia. The brain showed severe atrophy and
weighed 775 g. Tubing for the delivery system for PPS passed
through the brain into the lateral ventricles. The other main
organs were unremarkable.
Examination of the ﬁxed brain showed marked atrophy of the
cerebral and cerebellar hemispheres, brainstem and midbrain.
Figure 1 Duration of illness in cases
of variant Creutzfeldt-Jakob disease
(vCJD) (n=176).
Figure 2 Prion protein (PrP) immunohistochemistry in the frontal
cortex of the brain shows extensive deposition of disease-associated
PrP (brown) in large ﬂorid plaques (arrows), cluster plaques (large
arrowheads) and ﬁne granular deposits (small arrowheads). 3F4
anti-PrP antibody with haematoxylin counterstain,×40.
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On cross section, the hippocampus was relatively spared, but
the deep grey matter nuclei of the cerebral hemispheres were
atrophic and the subcortical white matter was ﬁrm and disco-
loured. No evidence of old or recent haemorrhage was identi-
ﬁed. Microscopic examination conﬁrmed marked atrophy of the
major grey matter structures, accompanied by severe neuronal
loss and widespread gliosis. The white matter was also markedly
gliotic and showed secondary myelin loss as a consequence of
axonal degeneration. Immunocytochemistry for PrP showed
massive accumulation of abnormal PrP throughout the cerebral
cortex and cerebellum, and also in the basal ganglia, thalamus
and hypothalamus and to a lesser extent the brainstem. The
pattern of deposition included ﬂorid plaques, small cluster
plaques and some granular deposits (ﬁgure 2).
Sections of the appendix, lymph nodes, spleen and tonsil
showed no evidence of abnormal PrP accumulation on routine
immunohistochemistry. However, repeat immunohistochemical
studies using an enhanced visualisation system showed PrP accu-
mulation in follicular dendritic cells within the tonsil, lymph
node, appendix and spleen.11 The spleen showed depletion of
white pulp, with sparse follicular labelling (ﬁgure 3), which was
conﬁrmed on parafﬁn-embedded tissue blot studies for prote-
ase-resistant prion proteinres. Western blot analysis of frozen
tissue samples from the cerebrum and cerebellum found high
levels of PrPres with a type 2B isoform characteristic of vCJD,12
with highest levels in the occipital cortex and lowest levels in
the thalamus. No speciﬁc signals for type 2B PrPres were
obtained using the centrifugal enrichment method on samples
of appendix, tonsil, lymph node or spleen. The sodium phos-
photungstic acid precipitation method allowed for detection of
type 2B PrPres in the spleen, but not in appendix, lymph node
or tonsil samples (ﬁgure 4). The patient was a methionine
homozygote at codon 129 in the PrP gene.
The pathological features conﬁrmed the diagnosis of vCJD.
DISCUSSION
The data presented in this paper suggests that treatment with
iPPS may extend survival in vCJD. Four out of ﬁve treated
patients survived for periods signiﬁcantly longer than untreated
patients (ﬁgure 1) and this suggests that chance alone is an
unlikely explanation. All the treated cases received excellent
nursing care, assisted feeding and active treatment of intercur-
rent illness, but this was also true for many of the ‘untreated’
cases of vCJD . There is an inverse relationship between age
and survival in human prion diseases13 and the three longest
survivors treated with iPPS were aged less than 20 years at the
time of starting treatment. However, there have been 31 other
cases of vCJD in the UK with an onset age less than 20 years in
which the mean survival was only 20 months. Many of these
cases received active treatment (but not iPPS) from an early
stage and case selection is unlikely to explain the extended sur-
vival in the iPPS group.
If iPPS inﬂuences the underlying disease process, the evidence
from the postmortem examination of the brain in this case does
not suggest that the treatment has reduced the extent or severity
of the brain pathology. In fact the pathological changes were
severe including the extent of abnormal PrP deposition and this
perhaps parallels the observed neurological deterioration in the
index case and the severe neurological deﬁcits present in the
latter stages of the illness. One potential explanation for the
extended survival is that iPPS treatment resulted in relative pres-
ervation of the brainstem nuclei and the sudden death, without
a clear cause on the general autopsy, may indicate that death
may have been due to a combination of central and peripheral
processes.
The relative paucity of abnormal PrP in lymphoreticular
system (LRS) might be as a result of the systemic treatment with
PPS. However, atrophy of LRS in chronic illness is well recog-
nised14 and it may be that the depletion of white matter pulp,
observed in this case, may reﬂect a more general atrophy of LRS
as an epiphenomenon rather than an effect of PPS treatment on
the levels of peripheral abnormal PrP. The blood-based assay for
vCJD has a reported sensitivity of 71% in known cases of
vCJD, therefore no clear conclusion can be drawn from this test
being negative10
In conclusion the evidence suggests that iPPS treatment may
have extended survival in vCJD and that this is likely related to
an effect on the underlying disease process. Although iPPS is
clearly not a cure for vCJD, the fact that such a treatment has
had a signiﬁcant biological effect provides encouragement for
the future development of treatment for human prion diseases.
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